Pressemitteilungen von Aji Bio-Pharma Pressemitteilungen February 22, 2023 Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase Weiterlesen January 10, 2023 Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Weiterlesen March 3, 2022 Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’ Weiterlesen January 25, 2022 Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance Weiterlesen 25. Mai 2021 Ajinomoto Bio-Pharma Services erweitert seine Abfüll- und Verpackungskapazitäten mit einer neuen Mehrzweck-Abfüllanlage Weiterlesen March 30, 2021 Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing Weiterlesen March 29, 2021 Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines Weiterlesen 27. Januar 2021 Ajinomoto Bio-Pharma Services und Humanigen erweitern ihre Produktionsvereinbarung zur Unterstützung der Abfüllung und Endverpackung des COVID-19-Prüfpräparats Lenzilumab, dessen Phase-3-Studie kurz vor dem Abschluss steht Weiterlesen December 22, 2020 Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection Weiterlesen October 6, 2020 First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval Weiterlesen September 29, 2020 Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic Weiterlesen August 13, 2020 Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility Weiterlesen Wird geladen…Mehr laden
